Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study - Wikidata - wikimedia - TriplyDB

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

http://www.wikidata.org/entity/Q28301602

about

Hypomethylating agents for patients with myelodysplastic syndrome Hypomethylating agents for patients with myelodysplastic syndrome Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome Decitabine in the treatment of myelodysplastic syndromes A phase 2 study of vorinostat in acute myeloid leukemia Epigenetic therapy in gastrointestinal cancer: the right combination Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials Physiological and pathological implications of 5-hydroxymethylcytosine in diseases DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma Epigenetic Control of Haematopoietic Stem Cell Aging and Its Clinical Implications Spotlight on decitabine for myelodysplastic syndromes in Chinese patients Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Beyond hypomethylating agents failure in patients with myelodysplastic syndromes New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome Infections in myelodysplastic syndromes Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives Myelodysplastic syndromes: what do hospitalists need to know?Epigenetics meets radiation biology as a new approach in cancer treatment The role of DNA methylation in aging, rejuvenation, and age-related disease Epigenetic regulation of hematopoietic stem cell aging Predicting response to epigenetic therapy Novel epigenetic target therapy for prostate cancer: a preclinical study Recurrent DNMT3A mutations in patients with myelodysplastic syndromes DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Therapy-related myeloid neoplasms - what have we learned so far?Epigenetic modulators as therapeutic targets in prostate cancer The many faces of hematopoietic stem cell heterogeneity Feasibility of therapy with hypomethylating agents in patients with renal insufficiency Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds

P2860

Q24186276-95216428-16FD-45C1-9CA1-D991D56FC2C5 Q24236549-CE72A320-FBD3-428D-9643-F571A8D5DB86 Q24608659-FFBC035A-AEDA-4E5D-AD3D-71FEAC95610F Q24622700-41E34272-1822-4A77-9A8F-012BCABFDF94 Q24632949-BAF47925-17D1-4838-BD41-E63EB0587061 Q24641906-F4E4F539-5A29-4611-99E3-3ADFC9931B17 Q24643266-4F2E64EB-AF32-4F01-A19D-311DBC3085B7 Q26745709-F357B321-8245-45B5-9E56-B55A8F1FA489 Q26745731-4DA2370B-789B-4B71-AF6E-4566F3F22B05 Q26749375-AD22226C-E18F-4190-B2E2-50E6021EDEC7 Q26749421-15402B19-E339-49DF-AC41-15766BFDCA47 Q26766068-6268373D-0625-4FA0-8EE7-F63D33ED94F0 Q26774949-320786FC-AC69-484F-B391-8580DA2B00DF Q26778454-5AD791C7-59D4-4893-AA45-1CE2CA4285A9 Q26783490-ADF9AD38-86EE-408C-9CED-42AAC075F651 Q26796240-474502B9-1175-46E5-8637-ECC56BBD9CBD Q26797616-1E7DD8EC-E1AD-437A-9D12-F757693C780F Q26801573-74719B8C-B80C-4C0B-9799-14BC6E03C08E Q26827079-F7017186-35C0-42CC-91EA-8E9D3A32F941 Q26829132-34612606-80CF-4EFD-98C8-14040ADD162A Q26859275-AD31DDB8-5D5C-47B9-88FD-47F72FFDBA19 Q26994739-A84E15B7-7620-4098-A3EC-BFE50C77A029 Q26999187-2113F91F-1111-468D-BFD7-8E9C8F87D181 Q27011372-8D11F498-9BC3-414B-B839-2FD99B1AD52E Q27014984-E188F5F4-17DD-4520-B97A-448D789E65FB Q27025194-D2088A3F-67F7-40A2-B16F-2E62A884A92D Q27026054-81427714-6445-44A2-BFBC-C30E7B78397A Q27027751-FED739FD-620C-4B27-AEEA-25FC9C2A6BAD Q27330048-E11F46BB-180C-47E6-B5FC-1040A3365B2D Q27851629-85891026-2B33-4D6A-8747-277881ABDED4 Q27851689-D58D69C4-18E3-4439-B7A4-A4B5201145D3 Q28071318-A14C0577-0591-4A15-B366-59D16CF8EE13 Q28071912-9EF5EDEA-949B-4DEB-ADCE-2374C6FABA21 Q28077078-D4338C42-396A-43EA-BE33-5950448F4B75 Q28283836-34E88F54-ED11-47CC-B53A-DECD5333CCA0 Q28307278-39EA5322-6821-4FBD-9B00-3A885E82930D Q28391216-1456C98A-A62D-401D-BD21-051B906142C6 Q28472733-AA9D47D2-EC18-4CD3-90F5-724F27CA4BF7 Q28475641-ECF2CF4B-BBBE-481A-AE6B-32A35EC7244D Q28477252-E1EB950F-BB5E-4DF2-988B-B34D950FB2EF

P2860

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

http://www.wikidata.org/entity/Q28301602

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Decitabine improves patient ou ...... f a phase III randomized study

@ast

Decitabine improves patient ou ...... f a phase III randomized study

@en

Decitabine improves patient ou ...... f a phase III randomized study

@nl

type

label

Decitabine improves patient ou ...... f a phase III randomized study

@ast

Decitabine improves patient ou ...... f a phase III randomized study

@en

Decitabine improves patient ou ...... f a phase III randomized study

@nl

prefLabel

Decitabine improves patient ou ...... f a phase III randomized study

@ast

Decitabine improves patient ou ...... f a phase III randomized study

@en

Decitabine improves patient ou ...... f a phase III randomized study

@nl

P1433

Q28301602-AAE61B2C-DE30-46A9-94C7-BE07FA15693F

P1476

Q28301602-A53D000C-EC0A-4455-8E5E-50CA77BBA11F

P2093

Q28301602-2A06BC0D-5DDD-4CF8-8B1B-01911961C481

Q28301602-41CBC3F4-F8EB-4C76-B469-2098D12A5E61

Q28301602-601252E3-E490-42A6-B42F-E968A39EDC28

Q28301602-6D028AA1-DFF0-48FF-8B8D-C57B27AA3D24

Q28301602-747A6921-E667-4B16-8FF4-DDC72B037F46

Q28301602-7696C2C1-88A9-4A3E-AAEB-E205EFF684AC

Q28301602-790D306D-6599-4071-9A24-59CC8CA5B35C

Q28301602-84A77268-B3B8-49BB-A982-0ED0107208C5

Q28301602-93F280AF-B7C1-435F-B758-047F2FAB161D

Q28301602-C143DF40-6380-4AAB-9F1D-69357512BC44

P2860

Q28301602-D6BDEA02-C8A4-4EB3-882C-DAE4857D5AD4

P304

Q28301602-4AD3B1BA-B456-4DFF-A34C-01D8D21C9F08

P31

Q28301602-823F20E1-8B27-4510-B592-C8C4CF7F1DE6

P3181

Q28301602-665F523E-3540-4AC7-A0FE-1CA84E9D6A8D

P356

Q28301602-49C07685-3CF5-46A4-89B2-744A6127B353

P407

Q28301602-A7B4F1B7-6982-4F51-8E42-0B865E449352

P433

Q28301602-DBDFF11C-9431-41FF-9E60-BBF2DD593484

P478

Q28301602-10FE9A8C-E884-4F39-91C4-FB1F93D90A3C

P50

Q28301602-1C834FF3-DD66-4930-BC27-2C4E285B99B4

Q28301602-6ED6E910-EE47-4CAA-86E5-3E35D4A80545

Q28301602-8E299ECB-8D35-4D45-AA64-A38BE62817EA

P577

Q28301602-23CFE62E-BDFC-4045-80A1-4649AC1AD762

P5875

Q28301602-D8B1A98E-678A-4A50-A433-3DF801D6102F

P698

Q28301602-D64721A8-8411-44A3-905B-C637195EB969

P921

Q28301602-3E18F457-2A3E-4782-920C-3965829BC86B

P3181

P356

P1433

P1476

Decitabine improves patient ou ...... f a phase III randomized study

@en

P2093

Azra Raza

http://www.w3.org/2001/XMLSchema#string

Carlos de Castro

http://www.w3.org/2001/XMLSchema#string

Craig S Rosenfeld

http://www.w3.org/2001/XMLSchema#string

Hussain Saba

http://www.w3.org/2001/XMLSchema#string

James Slack

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre J Issa

http://www.w3.org/2001/XMLSchema#string

John DiPersio

http://www.w3.org/2001/XMLSchema#string

John M Bennett

http://www.w3.org/2001/XMLSchema#string

Lanlan Shen

http://www.w3.org/2001/XMLSchema#string

Richard Helmer

http://www.w3.org/2001/XMLSchema#string

P2860

Proposals for the classification of the myelodysplastic syndromes

P304

1794-803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

792158

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/CNCR.21792

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

P577

2006-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7245050

http://www.w3.org/2001/XMLSchema#string

P698

16532500

http://www.w3.org/2001/XMLSchema#string

P921